

James R Cerhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5975961/publications.pdf>

Version: 2024-02-01

474
papers

26,634
citations

7069

78
h-index

8370

147
g-index

477
all docs

477
docs citations

477
times ranked

28872
citing authors

#	ARTICLE	IF	CITATIONS
1	High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL). <i>Leukemia</i> , 2022, 36, 165-176.	3.3	22
2	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2022, 36, 119-125.	3.3	10
3	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
4	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. <i>Leukemia</i> , 2022, , .	3.3	1
5	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
6	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1103-1110.	1.1	4
7	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
8	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	2.8	1
9	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
10	A (modifiable) way to better Hodgkin lymphoma survivorship?. <i>Blood</i> , 2022, 139, 3004-3005.	0.6	0
11	Computational drug repurposing based on electronic health records: a scoping review. <i>Npj Digital Medicine</i> , 2022, 5, .	5.7	16
12	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	2.5	2
13	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
14	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	0.6	6
15	Associations between tissue-based CD3+ Tâ€¦ lymphocyte count and colorectal cancer survival in a prospective cohort of older women. <i>Molecular Carcinogenesis</i> , 2021, 60, 15-24.	1.3	1
16	Testicular ^{FDGâ€¦PET}/^{CT} uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	2.0	3
17	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
18	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	2.8	9

#	ARTICLE	IF	CITATIONS
19	No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 229-237.	0.4	7
20	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	2.3	4
21	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021, 50, 1325-1334.	0.9	4
22	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
23	Epidemiology of marginal zone lymphoma. <i>Annals of Lymphoma</i> , 2021, 5, 1-1.	4.5	51
24	Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival. <i>Blood Advances</i> , 2021, 5, 1729-1732.	2.5	6
25	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021, 137, 2046-2056.	0.6	16
26	Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 442-446.	1.2	9
27	Pathway to Ascertain the Role of Pharmacogenomics in Healthcare Utilization Outcomes [Response to Letter]. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 545-546.	0.4	0
28	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
29	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021, 96, 979-988.	2.0	5
30	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	0.6	5
31	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
32	Occupational insecticide exposure and risk of non-Hodgkin lymphoma: A pooled case-control study from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2021, 149, 1768-1786.	2.3	13
33	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
34	Lack of intrafollicular memory CD4 ⁺ T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	2.8	27
35	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021, 11, 140.	2.8	6
36	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	0.6	0
38	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. <i>Blood</i> , 2021, 138, 4020-4020.	0.6	0
39	Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. <i>Blood</i> , 2021, 138, 2632-2632.	0.6	7
40	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	1.1	1
41	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). <i>Blood</i> , 2021, 138, 3437-3437.	0.6	0
42	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	0.6	2
43	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
44	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	0.6	1
45	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	0.6	0
46	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	0.6	1
47	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. <i>Blood</i> , 2021, 138, 3739-3739.	0.6	0
48	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
49	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020, 29, 70-79.	1.4	17
50	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	2.9	22
51	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	1.5	5
52	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	2.8	18
53	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1581-1589.	0.6	4
54	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020, 29, 2761-2774.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	0.4	2
56	Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. <i>Blood</i> , 2020, 135, 1008-1018.	0.6	12
57	Impact of Diverse Data Sources on Computational Phenotyping. <i>Frontiers in Genetics</i> , 2020, 11, 556.	1.1	5
58	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. <i>Blood Cancer Journal</i> , 2020, 10, 39.	2.8	4
59	Characteristics Associated With Recruitment and Re-contact in Mayo Clinic Biobank. <i>Frontiers in Public Health</i> , 2020, 8, 9.	1.3	4
60	Epidemiology of Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 631-646.	0.9	23
61	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. <i>American Journal of Human Genetics</i> , 2020, 106, 264-271.	2.6	25
62	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal Bâ€cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020, 95, 906-917.	2.0	17
63	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1074-1078.	1.1	13
64	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020, 136, 16-18.	0.6	2
65	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
66	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
67	High-Dimensional and Single-Cell Transcriptome Analysis of AITL Tumor Microenvironment Reveals Cross Expansion of Novel Dysfunctional CD8+ T Cell Populations, Global Shift in B Cell Phenotypes. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
68	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
69	Molecular Epidemiology of AML: Association of Somatic Gene Mutations with Epidemiologic Exposures and Outcomes in the Mayo Clinic AML Epidemiology Cohort. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
70	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
71	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
72	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37.	0.6	0

#	ARTICLE	IF	CITATIONS
73	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
74	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
75	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
76	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
77	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.	0.6	0
78	Association of elevated serum free light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, 59.	2.8	9
79	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	0.6	28
80	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26
81	Cumulative Doses of Ionizing Radiation From Computed Tomography: A Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2011-2021.	1.4	16
82	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
83	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
84	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019, 30, 889-900.	0.8	4
85	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	0.6	55
86	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
87	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	2.0	19
88	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
89	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	0.8	142
90	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	1.4	87

#	ARTICLE	IF	CITATIONS
91	Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: cohort profile. <i>BMJ Open</i> , 2019, 9, e032707.	0.8	31
92	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. <i>Blood Cancer Journal</i> , 2019, 9, 102.	2.8	57
93	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	1.5	5
94	Maintenance rituximab or observation after frontline treatment with bendamustineàrituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
95	Prevalence, clinical characteristics and prognosis of EBVàpositive follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E62-E64.	2.0	15
96	Secondàline and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	1.2	51
97	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	1.3	6
98	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
99	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
100	Epidemiology of Aggressive Lymphomas. <i>Essentials</i> , 2019, , 3-40.	0.1	0
101	Malignant T-Cells and Normal Intratumoral T-Cells Have Similar Expression of Immune Checkpoint Molecules in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1517-1517.	0.6	7
102	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2896-2896.	0.6	2
103	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	0.6	0
104	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. <i>Blood</i> , 2019, 134, 2764-2764.	0.6	0
105	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	0.6	0
106	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	0.6	0
107	The CCND1 870G Risk Allele Is Enriched in African Individuals with Plasma Cell Dyscrasias. <i>Blood</i> , 2019, 134, 4362-4362.	0.6	0
108	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	0.6	3
110	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	0.6	0
111	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019, 134, 852-852.	0.6	0
112	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. <i>Blood</i> , 2019, 134, 1224-1224.	0.6	0
113	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	0.6	2
114	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). <i>Blood</i> , 2019, 134, 4010-4010.	0.6	1
115	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	5.1	165
116	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018, 131, 2541-2551.	0.6	21
117	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	0.6	130
118	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 739-746.	1.4	29
119	Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism. <i>European Journal of Haematology</i> , 2018, 101, 136-142.	1.1	25
120	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2018, 378, 241-249.	13.9	392
121	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
122	Case-control investigation of occupational exposure to chlorinated solvents and non-Hodgkin's lymphoma. <i>Occupational and Environmental Medicine</i> , 2018, 75, 415-420.	1.3	9
123	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. <i>Blood Cancer Journal</i> , 2018, 8, 26.	2.8	92
124	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	1.2	13
125	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	0.6	11
126	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	1.2	5

#	ARTICLE	IF	CITATIONS
127	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
128	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
129	Association between an individual housing-based socioeconomic index and inconsistent self-reporting of health conditions: a prospective cohort study in the Mayo Clinic Biobank. <i>BMJ Open</i> , 2018, 8, e020054.	0.8	12
130	Developing a Process for Returning Medically Actionable Genomic Variants to Latino Patients in a Federally Qualified Health Center. <i>Public Health Genomics</i> , 2018, 21, 77-84.	0.6	19
131	Association of mitochondrial DNA copy number with self-rated health status. <i>The Application of Clinical Genetics</i> , 2018, Volume 11, 121-127.	1.4	8
132	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	0.6	97
133	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
134	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
135	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	5.8	15
136	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. <i>Blood Cancer Journal</i> , 2018, 8, 96.	2.8	47
137	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
138	High-throughput screening of prostate cancer risk loci by single nucleotide polymorphisms sequencing. <i>Nature Communications</i> , 2018, 9, 2022.	5.8	66
139	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	1.2	20
140	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
141	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.4	34
142	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	0.8	13
143	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
144	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	0.6	4
146	Association of Clinical Epidemiologic Exposures and Overall Survival with Genome-Wide DNA Methylation Profiles in Acute Myeloid Leukemia: Analysis of the Mayo Clinic AML Epidemiology Cohort. <i>Blood</i> , 2018, 132, 3987-3987.	0.6	1
147	<i>FCGR3A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	0.8	9
148	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
149	Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017, 178, 394-402.	1.2	66
150	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	2.0	23
151	Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 622-631.	1.1	68
152	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
153	Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. <i>International Journal of Dermatology</i> , 2017, 56, 1125-1129.	0.5	12
154	Individual housing-based socioeconomic status predicts risk of accidental falls among adults. <i>Annals of Epidemiology</i> , 2017, 27, 415-420.e2.	0.9	35
155	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	0.6	1,084
156	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15
157	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontline immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	1.2	49
158	Prevalence of BCL-2/((H) Translocation in Healthy African Americans. <i>Annals of Hematology</i> , 2017, 96, 51-55.	0.8	1
159	Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study. <i>International Journal of Cancer</i> , 2017, 140, 23-33.	2.3	53
160	Germline genetic variation in <i>JAK2</i> as a prognostic marker in castration-resistant prostate cancer. <i>BJU International</i> , 2017, 119, 489-495.	1.3	8
161	Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 39-47.	0.4	19
162	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50

#	ARTICLE	IF	CITATIONS
163	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their <i>ALK</i> , <i>DUSP22</i> and <i>TP63</i> Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. <i>Blood</i> , 2017, 130, 822-822.	0.6	9
164	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	0.6	2
165	Heart Failure After Myocardial Infarction Associated With Increased Risk of Cancer. <i>Journal of the American College of Cardiology</i> , 2016, 68, 265-271.	1.2	154
166	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
167	Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	1.2	44
168	Employment Status as an Indicator of Recovery and Function One Year after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1690-1695.	2.0	51
169	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
170	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , 2016, 128, 1234-1245.	0.6	105
171	2016 US lymphoid malignancy statistics by World Health Organization subtypes. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 443-459.	157.7	791
172	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 776-781.	2.0	14
173	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	5.8	94
174	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	2.0	22
175	Polycyclic aromatic hydrocarbons: determinants of residential carpet dust levels and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2016, 27, 1-13.	0.8	20
176	Cholesterol Metabolism and Prostate Cancer Lethality. <i>Cancer Research</i> , 2016, 76, 4785-4790.	0.4	61
177	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 151-157.	1.1	3
178	Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. <i>Mayo Clinic Proceedings</i> , 2016, 91, 71-80.	1.4	20
179	A novel housing-based socioeconomic measure predicts hospitalisation and multiple chronic conditions in a community population. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 286-291.	2.0	41
180	Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Women's Health Study. <i>Modern Pathology</i> , 2016, 29, 516-527.	2.9	65

#	ARTICLE	IF	CITATIONS
181	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
182	Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer Epidemiology</i> , 2016, 40, 134-140.	0.8	63
183	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
184	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
185	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
186	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
187	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016, 128, 4772-4772.	0.6	4
188	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
189	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
190	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 920-920.	0.6	0
191	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	0.6	0
192	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
193	Isogenic Loss of TNFAIP3 in Waldenstrom Macroglobulinemia Enhances MYD88L265P-Driven Signaling. <i>Blood</i> , 2016, 128, 4100-4100.	0.6	0
194	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	0.6	68
195	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , 2015, 125, 658-667.	0.6	108
196	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
197	Familial predisposition and genetic risk factors for lymphoma. <i>Blood</i> , 2015, 126, 2265-2273.	0.6	122
198	Investigation of spatio-temporal cancer clusters using residential histories in a case-control study of non-Hodgkin lymphoma in the United States. <i>Environmental Health</i> , 2015, 14, 48.	1.7	8

#	ARTICLE	IF	CITATIONS
199	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. <i>European Journal of Haematology</i> , 2015, 95, 442-448.	1.1	30
200	Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia. <i>International Journal of Dermatology</i> , 2015, 54, e287-93.	0.5	40
201	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	2.0	221
202	Health behaviors and quality of life predictors for risk of hospitalization in an electronic health record-linked biobank. <i>International Journal of General Medicine</i> , 2015, 8, 247.	0.8	12
203	How well do whole exome sequencing results correlate with medical findings? A study of 89 Mayo Clinic Biobank samples. <i>Frontiers in Genetics</i> , 2015, 6, 244.	1.1	9
204	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
205	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1061-1070.	1.1	8
206	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 713-719.	1.1	10
207	Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: A Rochester Epidemiology Project population-based study in Minnesota. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 302-309.	0.6	74
208	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. <i>American Journal of Epidemiology</i> , 2015, 181, 406-421.	1.6	54
209	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	0.8	610
210	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	0.6	2
211	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	0.8	24
212	Quantifying the importance of disease burden on perceived general health and depressive symptoms in patients within the Mayo Clinic Biobank. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 95.	1.0	11
213	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	0.6	22
214	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015, 56, 434-439.	0.6	14
215	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	0.6	6
216	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1

#	ARTICLE	IF	CITATIONS
217	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. <i>Blood</i> , 2015, 126, 5265-5265.	0.6	4
218	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	0.6	0
219	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	0.6	0
220	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	0.6	0
221	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	2.0	16
222	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 15-25.	0.9	98
223	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 1-14.	0.9	52
224	Allergic Diseases and Risk of Hematopoietic Malignancies in a Cohort of Postmenopausal Women: A Report from the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1903-1912.	1.1	10
225	Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 115-124.	0.9	31
226	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 26-40.	0.9	151
227	Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort. <i>International Journal of Cancer</i> , 2014, 134, 1741-1750.	2.3	42
228	Pooling Prospective Studies to Investigate the Etiology of Second Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1598-1608.	1.1	9
229	Identifying gender differences in reported occupational information from three US population-based case-control studies. <i>Occupational and Environmental Medicine</i> , 2014, 71, 855-864.	1.3	25
230	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , 2014, 30, 3414-3416.	1.8	34
231	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	3.2	86
232	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Marginal Zone Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 52-65.	0.9	70
233	A Pooled Analysis of Waist Circumference and Mortality in 650,000 Adults. <i>Mayo Clinic Proceedings</i> , 2014, 89, 335-345.	1.4	307
234	B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidylinositol 3-kinase pathway in lymphoma B cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 1884-1892.	0.6	6

#	ARTICLE	IF	CITATIONS
235	Associations between Cigarette Smoking, Hormone Therapy, and Folate Intake with Incident Colorectal Cancer by TP53 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 350-355.	1.1	11
236	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	2.0	26
237	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
238	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
239	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
240	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	0.8	144
241	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 41-51.	0.9	82
242	Farm residence and lymphohematopoietic cancers in the Iowa Women's Health Study. <i>Environmental Research</i> , 2014, 133, 353-361.	3.7	26
243	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014, 30, 2678-2680.	1.8	43
244	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014, 120, 2000-2005.	2.0	33
245	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
246	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	0.6	401
247	Elevated soluble IL-2, IL-8, and MIP-1 β levels are associated with inferior outcome and are independent of MIP-1 score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
248	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 2998-2998.	0.6	2
249	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	2.0	28
250	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
251	Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women. <i>Gastroenterology</i> , 2013, 145, 348-356.e2.	0.6	49
252	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. <i>Cancer Causes and Control</i> , 2013, 24, 125-134.	0.8	20

#	ARTICLE	IF	CITATIONS
253	Hospitalizations and Emergency Department Use in Mayo Clinic Biobank Participants Within the Employee and Community Health Medical Home. Mayo Clinic Proceedings, 2013, 88, 963-969.	1.4	11
254	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. Cytokine, 2013, 64, 523-531.	1.4	16
255	The Mayo Clinic Biobank: A Building Block for Individualized Medicine. Mayo Clinic Proceedings, 2013, 88, 952-962.	1.4	180
256	Overall and Cancer-Specific Survival of Patients With Breast, Colon, Kidney, and Lung Cancers With and Without Chronic Lymphocytic Leukemia: A SEER Population-Based Study. Journal of Clinical Oncology, 2013, 31, 930-937.	0.8	56
257	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876.	9.4	179
258	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leukemia and Lymphoma, 2013, 54, 2571-2573.	0.6	7
259	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2013, 54, 290-297.	0.6	58
260	Mapping of the <i>IRF8</i> Gene Identifies a 3'UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 461-466.	1.1	13
261	Leveraging Epidemiology and Clinical Studies of Cancer Outcomes: Recommendations and Opportunities for Translational Research. Journal of the National Cancer Institute, 2013, 105, 85-94.	3.0	46
262	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. Clinical Cancer Research, 2013, 19, 6812-6819.	3.2	64
263	trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma. Journal of Nutrition, 2013, 143, 672-681.	1.3	36
264	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. Blood, 2013, 121, 237-238.	0.6	10
265	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2867-2867.	0.6	4
266	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	0.6	2
267	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	0.6	0
268	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. Blood, 2013, 122, 76-76.	0.6	1
269	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. Blood, 2013, 122, 1703-1703.	0.6	0
270	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. Blood, 2013, 122, 1784-1784.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. <i>Blood</i> , 2013, 122, 4288-4288.	0.6	0
272	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. <i>Blood</i> , 2013, 122, 1774-1774.	0.6	0
273	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. <i>Blood</i> , 2013, 122, 3058-3058.	0.6	0
274	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013, 122, 626-626.	0.6	0
275	Activation Of TAK1 By MYD88 L265P Drives Malignant B Cell Growth In Non-Hodgkin Lymphomas. <i>Blood</i> , 2013, 122, 245-245.	0.6	1
276	Copy Number Abnormalities Of The Interferon Regulatory Factor-4 (IRF4) Gene Are Associated With IRF4/MUM1 Expression In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 3016-3016.	0.6	0
277	Associations Between Intake of Folate and Related Micronutrients with Molecularly Defined Colorectal Cancer Risks in the Iowa Women's Health Study. <i>Nutrition and Cancer</i> , 2012, 64, 899-910.	0.9	33
278	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	3.3	853
279	LIM domain only 2 protein expression, <i>i>LMO2</i> germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i>, 2012, 53, 1105-1112.</i>	0.6	5
280	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. <i>Blood</i> , 2012, 120, 4645-4648.	0.6	34
281	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1799-1806.	1.1	22
282	Chronic Lymphocytic Leukemia Is Associated With Decreased Survival of Patients With Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 843-849.	0.8	107
283	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 843-846.	0.6	76
284	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. <i>Blood</i> , 2012, 119, 469-475.	0.6	66
285	Self-reported history of infections and the risk of non-Hodgkin lymphoma: An InterLymph pooled analysis. <i>International Journal of Cancer</i> , 2012, 131, 2342-2348.	2.3	23
286	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. <i>British Journal of Haematology</i> , 2012, 159, n/a-n/a.	1.2	13
287	Postmenopausal Hormone Therapy and Colorectal Cancer Risk in Relation to Somatic <i><i>KRAS</i> Mutation Status among Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i>, 2012, 21, 681-684.</i>	1.1	25
288	Cigarette Smoking and Colorectal Cancer Risk by KRAS Mutation Status Among Older Women. <i>American Journal of Gastroenterology</i> , 2012, 107, 782-789.	0.2	32

#	ARTICLE	IF	CITATIONS
289	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. <i>Gut</i> , 2012, 61, 1299-1305.	6.1	36
290	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. <i>Annals of Epidemiology</i> , 2012, 22, 855-862.	0.9	19
291	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	1.4	50
292	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1071-1079.	1.4	94
293	A comprehensive study of polymorphisms in the <i>ABCB1</i> , <i>ABCC2</i> , <i>ABCG2</i> , <i>NR112</i> genes and lymphoma risk. <i>International Journal of Cancer</i> , 2012, 131, 803-812.	2.3	35
294	Food frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2012, 131, 1158-1168.	2.3	37
295	Inherited genetic variation and overall survival following follicular lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 724-726.	2.0	13
296	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
297	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	2.0	36
298	Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012, 23, 1017-1029.	0.8	34
299	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	0.6	1
300	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	0.6	0
301	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	0.6	0
302	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012, 120, 1573-1573.	0.6	0
303	Alcohol Intake and Colorectal Cancer Risk by Molecularly Defined Subtypes in a Prospective Study of Older Women. <i>Cancer Prevention Research</i> , 2011, 4, 2035-2043.	0.7	17
304	Host genetics in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 121-134.	0.7	9
305	Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. <i>Scientific World Journal</i> , The, 2011, 11, 2062-2070.	0.8	12
306	Variation in Effects of Non-Hodgkin Lymphoma Risk Factors According to the Human Leukocyte Antigen (HLA)-DRB1*01:01 Allele and Ancestral Haplotype 8.1. <i>PLoS ONE</i> , 2011, 6, e26949.	1.1	11

#	ARTICLE	IF	CITATIONS
307	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
308	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	0.6	118
309	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	0.6	50
310	Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies. <i>British Journal of Haematology</i> , 2011, 153, 341-350.	1.2	34
311	A pooled analysis of three studies evaluating genetic variation in innate immunity genes and non-Hodgkin lymphoma risk. <i>British Journal of Haematology</i> , 2011, 152, 721-726.	1.2	29
312	Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 149-155.	1.1	82
313	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
314	Risk factors for non-Hodgkin lymphoma subtypes defined by histology and t(14;18) in a population-based case-control study. <i>International Journal of Cancer</i> , 2011, 129, 938-947.	2.3	14
315	Variations in Chromosomes 9 and 6p21.3 with Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 42-49.	1.1	17
316	Nonsteroidal Anti-inflammatory Drug and Acetaminophen Use and Risk of Adult Myeloid Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1741-1750.	1.1	28
317	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70
318	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. <i>PLoS Genetics</i> , 2011, 7, e1001378.	1.5	93
319	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	0.6	26
320	Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004-2007. <i>Blood</i> , 2011, 118, 3708-3708.	0.6	24
321	Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL). <i>Blood</i> , 2011, 118, 775-775.	0.6	7
322	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. <i>Blood</i> , 2011, 118, 97-97.	0.6	10
323	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients. <i>Blood</i> , 2011, 118, 3903-3903.	0.6	0
324	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570.	0.6	15

#	ARTICLE	IF	CITATIONS
325	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	0.6	1
326	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. <i>Blood</i> , 2011, 118, 3881-3881.	0.6	0
327	A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes. <i>Blood</i> , 2011, 118, 2642-2642.	0.6	0
328	Elevated Monoclonal Free Light Chains Are a Serum Marker of ABC Type Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 1591-1591.	0.6	0
329	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011, 118, 4610-4610.	0.6	0
330	The Mutational Landscape of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 259-259.	0.6	0
331	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 95-113.	0.4	37
332	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 245-52.	0.4	7
333	Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. <i>International Journal of Cancer</i> , 2010, 126, 992-1003.	2.3	73
334	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. <i>Blood</i> , 2010, 115, 4820-4823.	0.6	68
335	A case-control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression. <i>Cancer Causes and Control</i> , 2010, 21, 1147-1154.	0.8	9
336	Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 2993-3000.	2.0	68
337	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. <i>British Journal of Haematology</i> , 2010, 151, 152-158.	1.2	61
338	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. <i>Nature Genetics</i> , 2010, 42, 661-664.	9.4	152
339	Genetic Susceptibility Variants for Chronic Lymphocytic Leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1098-1102.	1.1	31
340	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010, 207, 2569-2579.	4.2	96
341	Linking the Iowa Women's Health Study Cohort to Medicare Data: Linkage Results and Application to Hip Fracture. <i>American Journal of Epidemiology</i> , 2010, 172, 327-333.	1.6	35
342	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2010, 28, 412-417.	0.8	75

#	ARTICLE	IF	CITATIONS
343	Body-Mass Index and Mortality among 1.46 Million White Adults. <i>New England Journal of Medicine</i> , 2010, 363, 2211-2219.	13.9	1,926
344	Birth Order and Risk of Non-Hodgkin Lymphoma—True Association or Bias?. <i>American Journal of Epidemiology</i> , 2010, 172, 621-630.	1.6	22
345	Cigarette Smoking and Colorectal Cancer Risk by Molecularly Defined Subtypes. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1012-1022.	3.0	261
346	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2847-2858.	1.1	39
347	Body Size and Incident Colorectal Cancer: A Prospective Study of Older Women. <i>Cancer Prevention Research</i> , 2010, 3, 1608-1620.	0.7	51
348	Reply to J.R. Carver et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e612-e612.	0.8	0
349	Tumor Necrosis Factor (TNF) and Lymphotoxin- α (LTA) Polymorphisms and Risk of Non-Hodgkin Lymphoma in the InterLymph Consortium. <i>American Journal of Epidemiology</i> , 2010, 171, 267-276.	1.6	128
350	InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. <i>Blood</i> , 2010, 116, e90-e98.	0.6	200
351	Reply to C. Barker et al and H. Asai et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e427-e428.	0.8	0
352	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
353	Fruit and vegetable intake and survival from non-Hodgkin lymphoma: does an apple a day keep the doctor away?. <i>Leukemia and Lymphoma</i> , 2010, 51, 963-964.	0.6	6
354	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	0.6	2
355	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	0.6	1
356	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 2409-2409.	0.6	0
357	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
358	Significant Recent Declines In Adult Leukemia Incidence Rates In the United States. <i>Blood</i> , 2010, 116, 873-873.	0.6	0
359	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. <i>Blood</i> , 2010, 116, 4136-4136.	0.6	0
360	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010, 116, 468-468.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci. <i>Blood</i> , 2010, 116, 2443-2443.	0.6	0
362	Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS). <i>Blood</i> , 2010, 116, 1768-1768.	0.6	2
363	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 4127-4127.	0.6	0
364	Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1259-1270.	1.1	59
365	Functional and Clinical Significance of Variants Localized to 8q24 in Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2492-2500.	1.1	37
366	Atopic Disease and Risk of Non-Hodgkin Lymphoma: An InterLymph Pooled Analysis. <i>Cancer Research</i> , 2009, 69, 6482-6489.	0.4	86
367	Genetic Variation in B-Cell-Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2009, 69, 4217-4224.	0.4	59
368	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	0.8	263
369	Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2009, 20, 1291-1302.	0.8	15
370	Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. <i>British Journal of Haematology</i> , 2009, 145, 614-623.	1.2	15
371	Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. <i>Blood</i> , 2009, 114, 264-267.	0.6	42
372	A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2009, 30, 275-281.	1.3	75
373	Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2009, 113, 1899-1905.	0.6	39
374	Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.. <i>Blood</i> , 2009, 114, 1232-1232.	0.6	2
375	Common Gene Variants in the Tumor Necrosis Factor (TNF) and TNF Receptor Superfamilies and NF-kB Transcription Factors and Non-Hodgkin Lymphoma Risk. <i>PLoS ONE</i> , 2009, 4, e5360.	1.1	88
376	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 1952-1952.	0.6	0
377	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3933-3933.	0.6	1
378	Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.. <i>Blood</i> , 2009, 114, 1241-1241.	0.6	0

#	ARTICLE	IF	CITATIONS
379	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	0.6	0
380	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. Blood, 2009, 114, 440-440.	0.6	4
381	Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph Consortium. International Journal of Cancer, 2008, 122, 2062-2070.	2.3	104
382	Vegetables- and antioxidant-related nutrients, genetic susceptibility, and non-Hodgkin lymphoma risk. Cancer Causes and Control, 2008, 19, 491-503.	0.8	14
383	Personal sun exposure and risk of non Hodgkin lymphoma: A pooled analysis from the Interlymph Consortium. International Journal of Cancer, 2008, 122, 144-154.	2.3	152
384	Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study. International Journal of Cancer, 2008, 123, 888-894.	2.3	18
385	Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood, 2008, 111, 4029-4038.	0.6	508
386	Hepatitis C and Non-Hodgkin Lymphoma Among 4784 Cases and 6269 Controls From the International Lymphoma Epidemiology Consortium. Clinical Gastroenterology and Hepatology, 2008, 6, 451-458.	2.4	313
387	Relative Weight at Age 12 and Risk of Postmenopausal Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 374-378.	1.1	48
388	Genetic Variation in Tumor Necrosis Factor and the Nuclear Factor- κ B Canonical Pathway and Risk of Non-Hodgkin's Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3161-3169.	1.1	66
389	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood, 2008, 112, 2694-2702.	0.6	64
390	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 2008, 112, 5150-5160.	0.6	148
391	Dietary flavonoid intake and non-Hodgkin lymphoma risk. American Journal of Clinical Nutrition, 2008, 87, 1439-1445.	2.2	45
392	Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2008, 112, 583-583.	0.6	2
393	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. Blood, 2008, 112, 3771-3771.	0.6	0
394	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 2007, 110, 695-708.	0.6	365
395	Two Common Chromosome 8q24 Variants Are Associated with Increased Risk for Prostate Cancer. Cancer Research, 2007, 67, 2944-2950.	0.4	100
396	Census and Geographic Differences between Respondents and Nonrespondents in a Case-Control Study of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2007, 167, 350-361.	1.6	26

#	ARTICLE	IF	CITATIONS
397	Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality. <i>Journal of the National Cancer Institute</i> , 2007, 99, 881-889.	3.0	76
398	Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2007, 28, 1759-1764.	1.3	39
399	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007, 109, 3479-3488.	0.6	159
400	Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2007, 110, 4455-4463.	0.6	144
401	Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. <i>Blood</i> , 2007, 109, 5439-5446.	0.6	109
402	Immune Mechanisms in Non-Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non-Hodgkin Lymphoma Risk Factors. <i>Cancer Research</i> , 2007, 67, 5042-5054.	0.4	57
403	Susceptibility genes and Chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 139, 762-771.	1.2	26
404	Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2007, 18, 989-999.	0.8	41
405	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21. <i>Blood</i> , 2007, 110, 3585-3585.	0.6	1
406	Host Genetic Variation in the Cell Cycle and NF- κ B Pathways and Overall Survival in Mantle Cell Lymphoma. <i>Blood</i> , 2007, 110, 1582-1582.	0.6	0
407	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study. <i>Blood</i> , 2007, 110, 2615-2615.	0.6	0
408	Polymorphisms in One-Carbon Metabolism Genes and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2007, 110, 1568-1568.	0.6	1
409	Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. <i>Lancet Oncology</i> , 2006, 7, 27-38.	5.1	345
410	Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. <i>Carcinogenesis</i> , 2006, 27, 1828-1834.	1.3	113
411	Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma. <i>Cancer Research</i> , 2006, 66, 9771-9780.	0.4	124
412	Vegetables, fruit, and antioxidant-related nutrients and risk of non-Hodgkin lymphoma: a National Cancer Institute Surveillance, Epidemiology, and End Results population-based case-control study. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 1401-1410.	2.2	63
413	Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. <i>Blood</i> , 2006, 108, 3161-3167.	0.6	73
414	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 537-545.	0.7	48

#	ARTICLE	IF	CITATIONS
415	Ultraviolet radiation, dietary vitamin D, and risk of non-Hodgkin lymphoma (United States). <i>Cancer Causes and Control</i> , 2006, 17, 1045-1052.	0.8	61
416	Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. <i>Human Genetics</i> , 2006, 120, 297-300.	1.8	22
417	Meat and meat-mutagen intake and risk of non-Hodgkin lymphoma: results from a NCI-SEER case-control study. <i>Carcinogenesis</i> , 2006, 27, 293-297.	1.3	48
418	Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 935-938.	1.1	49
419	No Association Between 25-Hydroxyvitamin D and Mammographic Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1988-1992.	1.1	37
420	Elevated Serum B-Lymphocyte Stimulator Levels in Patients With Familial Lymphoproliferative Disorders. <i>Journal of Clinical Oncology</i> , 2006, 24, 983-987.	0.8	85
421	Metabolic Gene Variants and Risk of Non-Hodgkin's Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1647-1653.	1.1	59
422	Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2006, 108, 2028-2028.	0.6	0
423	Smoking, Obesity and Overall Survival in Non-Hodgkin Lymphoma (NHL): A Population-Based Study.. <i>Blood</i> , 2006, 108, 4649-4649.	0.6	0
424	Childhood Crowding, Atopy and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 4648-4648.	0.6	0
425	Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population-Based Study.. <i>Blood</i> , 2006, 108, 820-820.	0.6	0
426	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. <i>Blood</i> , 2006, 108, 2396-2396.	0.6	0
427	Adult Weight Gain and Risk of Developing Non-Hodgkin Lymphoma (NHL): Results from a Large Prospective Cohort Study of Older Women.. <i>Blood</i> , 2006, 108, 2389-2389.	0.6	0
428	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006, 108, 817-817.	0.6	0
429	Hormone replacement therapy is not associated with an increased risk of leukemia (United States). <i>Cancer Causes and Control</i> , 2005, 16, 483-488.	0.8	9
430	Anthropometrics, Physical Activity, Related Medical Conditions, and the Risk of Non-Hodgkin Lymphoma. <i>Cancer Causes and Control</i> , 2005, 16, 1203-1214.	0.8	69
431	Residential Herbicide Use and Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 934-937.	1.1	45
432	Immune-Related Conditions and Immune-Modulating Medications as Risk Factors for Non-Hodgkin's Lymphoma: A Case-Control Study. <i>American Journal of Epidemiology</i> , 2005, 162, 1153-1161.	1.6	94

#	ARTICLE	IF	CITATIONS
433	Prenatal and Perinatal Correlates of Adult Mammographic Breast Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1502-1508.	1.1	42
434	Cigarette Smoking and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis from the International Lymphoma Epidemiology Consortium (InterLymph). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 925-933.	1.1	164
435	Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. <i>Lancet Oncology</i> , The, 2005, 6, 469-476.	5.1	137
436	Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study.. <i>Blood</i> , 2005, 106, 1000-1000.	0.6	1
437	A Pilot Study of Physical Activity Level and Mood among Long-Term Lymphoma Survivors.. <i>Blood</i> , 2005, 106, 4692-4692.	0.6	2
438	Quality of Life Concerns of Long-Term Lymphoma Survivors: Results of a Pilot Study.. <i>Blood</i> , 2005, 106, 4695-4695.	0.6	1
439	Blood Transfusion, Anesthesia, Surgery and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005, 106, 4697-4697.	0.6	0
440	Beliefs, Attitudes and Utilization of Complementary and Alternative Medicine (CAM) among Long-Term Lymphoma Survivors: A Pilot Study.. <i>Blood</i> , 2005, 106, 4700-4700.	0.6	0
441	Interaction of adolescent anthropometric characteristics and family history on breast cancer risk in a Historical Cohort Study of 426 families (USA). <i>Cancer Causes and Control</i> , 2004, 15, 1-9.	0.8	11
442	Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2004, 50, 72-77.	6.7	666
443	Hepatitis C virus infection and non-hodgkin lymphoma: Results of the NCI-seer multi-center case-control study. <i>International Journal of Cancer</i> , 2004, 111, 76-80.	2.3	102
444	Response to ?Non-Hodgkin's lymphoma and nonsteroidal anti-inflammatory drugs: A confounding problem? by Harris. <i>International Journal of Cancer</i> , 2004, 110, 152-152.	2.3	0
445	Environmental exposure to PCBs and cancer incidence in eastern Slovakia. <i>Chemosphere</i> , 2004, 54, 1509-1520.	4.2	85
446	Novel twin study implicates IL-6 in the etiology of young adult Hodgkin lymphoma. <i>Blood</i> , 2004, 103, 2871-2872.	0.6	1
447	Elevated BLYS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLYS Polymorphisms.. <i>Blood</i> , 2004, 104, 964-964.	0.6	0
448	Estrogen Replacement Therapy (ERT) Is Not Associated with an Increased Risk of Leukemia.. <i>Blood</i> , 2004, 104, 1063-1063.	0.6	0
449	Adherence to the AICR cancer prevention recommendations and subsequent morbidity and mortality in the Iowa Women's Health Study cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1114-20.	1.1	37
450	Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1415-21.	1.1	70

#	ARTICLE	IF	CITATIONS
451	Body mass index and risk of leukemia in older women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1810-3.	1.1	27
452	Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-hodgkin lymphoma. <i>International Journal of Cancer</i> , 2003, 106, 784-788.	2.3	71
453	No association of germline alteration of MSR1 with prostate cancer risk. <i>Nature Genetics</i> , 2003, 35, 128-129.	9.4	60
454	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 202-210.	2.4	42
455	Antioxidant Micronutrients and Risk of Rheumatoid Arthritis in a Cohort of Older Women. <i>American Journal of Epidemiology</i> , 2003, 157, 345-354.	1.6	221
456	Cigarette smoking and colorectal cancer: Long-term, subsite-specific risks in a cohort study of postmenopausal women. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 202-210.	2.4	42
457	Anthropometric Characteristics, Physical Activity, and Risk of Non-Hodgkin's Lymphoma Subtypes and B-Cell Chronic Lymphocytic Leukemia: A Prospective Study. <i>American Journal of Epidemiology</i> , 2002, 156, 527-535.	1.6	100
458	Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women. <i>American Journal of Medicine</i> , 2002, 112, 465-471.	0.6	175
459	Analysis of the RNASEL Gene in Familial and Sporadic Prostate Cancer. <i>American Journal of Human Genetics</i> , 2002, 71, 116-123.	2.6	105
460	Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: Results from the Iowa Women's Health Study. <i>Arthritis and Rheumatism</i> , 2002, 46, 83-91.	6.7	147
461	Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). <i>Cancer Causes and Control</i> , 2002, 13, 131-136.	0.8	28
462	Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. <i>Journal of Rheumatology</i> , 2002, 29, 246-54.	1.0	97
463	Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 1466-71.	1.1	21
464	Tea Consumption and Risk of Cancer of the Colon and Rectum. <i>Nutrition and Cancer</i> , 2001, 41, 33-40.	0.9	25
465	Investigation of an interaction of alcohol intake and family history on breast cancer risk in the Minnesota Breast Cancer Family Study. <i>Cancer</i> , 2001, 92, 240-248.	2.0	40
466	Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women. <i>Leukemia and Lymphoma</i> , 2000, 37, 341-349.	0.6	48
467	Tea Consumption and Risk of Bladder and Kidney Cancers In a Population-based Case-Control Study. <i>American Journal of Epidemiology</i> , 2000, 151, 377-383.	1.6	78
468	An investigation of the biological basis of an interaction of abdominal fat distribution and family history of breast cancer. A nested study of sisters in the Iowa Women's Health Study (United States). <i>Cancer Causes and Control</i> , 2000, 11, 941-954.	0.8	5

#	ARTICLE	IF	CITATIONS
469	2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a Carcinogen in High- Temperature-Cooked Meat, and Breast Cancer Risk. Journal of the National Cancer Institute, 2000, 92, 1352-1354.	3.0	156
470	Twinship and Risk of Postmenopausal Breast Cancer. Journal of the National Cancer Institute, 2000, 92, 261-265.	3.0	49
471	Calcium-channel blockade and incidence of cancer in aged populations. Lancet, The, 1996, 348, 493-497.	6.3	341
472	Cancer Incidence Among Women Living on Farms: Findings from the Iowa Women's Health Study*. Journal of Occupational and Environmental Medicine, 1996, 38, 1171-1176.	0.9	39
473	Transfusion History and Cancer Risk in Older Women. Annals of Internal Medicine, 1993, 119, 8.	2.0	62
474	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. JCO Oncology Practice, 0, , .	1.4	0